Company Filing History:
Years Active: 2023-2024
Title: Michael Su: Innovator in ENPP1 Inhibitors
Introduction
Michael Su is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of inhibitors for ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). With a total of 2 patents, his work is paving the way for new therapeutic approaches.
Latest Patents
Michael Su's latest patents include "Heterocyclic inhibitors of ENPP1" and "Imino sulfanone inhibitors of ENPP1." The first patent relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1, focusing on their potential use in treating diseases mediated by this enzyme. The second patent discusses sulfoximine-based inhibitors of ENPP1, also aimed at addressing diseases linked to ENPP1 activity. Both patents highlight innovative methods and compositions that could lead to significant advancements in medical treatments.
Career Highlights
Michael Su is currently associated with Volastra Therapeutics, Inc., where he continues to explore and develop novel therapeutic strategies. His work is characterized by a strong emphasis on the practical applications of his inventions in the medical field.
Collaborations
Some of his notable coworkers include Derek A Cogan and Sarah Bettigole. Their collaborative efforts contribute to the innovative environment at Volastra Therapeutics, Inc., fostering advancements in therapeutic research.
Conclusion
Michael Su's contributions to the field of ENPP1 inhibitors exemplify the impact of innovative thinking in medicine. His patents represent a significant step forward in developing treatments for diseases mediated by ENPP1.